Arthritis can be improved with IP Group supported company – Yalla Match

Kathleen Turner was just 38 when her legs began to swell. Within weeks, she could not move her left arm, then her neck froze, and soon after, it became almost impossible for the Hollywood actress to walk.

It was the early 1990s, and when Turner was diagnosed with rheumatoid arthritis, an autoimmune disease, steroids were the only medication that could relieve her chronic pain.

Since then, other drugs have appeared on the market, but most of them work by switching the immune system off and on, causing long-term side effects.

The company was an outgrowth of the University of Aberdeen, and was backed from the start by IP Group, a FTSE 250 company dedicated to finding businesses in their early stages and helping them succeed.

Star patient: Kathleen Turner’s painful rheumatoid arthritis can be helped by IP group-backed drug company

The IP share is 69p, down 45% on last year. The drop is unjustified and the stock should rise.

The biggest IP success to date is Oxford Nanopore Technologies, DNA sequencers known for identifying and tracking Covid-19 variants.

Nanopore went public on the stock market last year and was valued at £3.5 billion, or £4.25 per share. The price is now £2.86, which is in line with other technology companies, but there is widespread agreement that the company’s technology is top notch and deserves a higher share price.

This will be a welcome boost for Intellectual Property, which founded Nanopore in 2005 and still owns 10% of the business. But this group has more conditions.

Istesso is an excellent example. Early trials of the new drug are promising, with a second phase starting this year and a final trial scheduled for 2024. Independent analysts say Istesso could be worth more than £1bn.

Other investments in our intellectual property portfolio also have great potential. Cambridge-based Feature Space, which uses artificial intelligence to combat financial fraud, is already profitable as the technology is deployed by giants such as HSBC and Worldpay.

Oxbotica, which develops self-driving software for heavy vehicles such as trucks and buses, has won numerous awards and is at the forefront of its sector, and Ocado is a major investor along with increasing IP.

Based in Oxford, First Light Fusion works on technology that mimics the way the sun produces energy to produce ultra-pure electricity. Pioneer has been working on this type of technology for years.

First Light appears to be closer to success than many and is seeking around £400 million in cash from outside investors to bring its technology closer to reality. If this funding is successful, First Light’s valuation will rise and the 27% intellectual property stake will be much more valuable.

IP doesn’t just continue to acquire new companies. It has also sold companies including Ceres Power, valued at around £1.2 billion in the stock market, and electric car specialist Yasa, which was sold to Mercedes-Benz last year.

The group was listed on the stock exchange in 2003 when the share price was around 60 pence and the asset value per share, known as Net Asset Value or NAV, 22 pence.

So the company was trading at a significant premium to the value of its assets at the time. NAV is now £1.37. However, the stock market argues that the company’s value is far below its independently valued assets, with a share price of just 69p.

That doesn’t sound right and CEO Greg Smith is determined to change that. After being promoted to CFO last year, he reached out to major IP contributors and asked what they would like to see in IP.

Following their suggestions, Smith simplified the company around healthcare, technology and green business. He showed where the company could succeed in the next few years, starting to pay dividends, invest in new technology, support growing companies and reward investors along the way. We have proven to investors that we can do it.

Midas rule: The UK is one of the world’s most innovative countries, but it lags far behind the US in turning ideas into successful businesses. IP is one of the few companies that can facilitate this process. At 69 pence the share is undervalued. UK investors have a chance to get it right. He buys.

Suppliers: The main market wiser: endorsement Call: or 020 7444 0050

Some of the links in this article may be affiliate links. If you click on it, you can earn a small commission. This helps fund This Is Money and make it free to use. I do not write articles to promote products. We do not allow any commercial relationships that affect our editorial independence.

Leave a Comment